Efficacy News and Research

RSS

Research finding suggests HCV interference with hepcidin synthesis

Iron overload, a common feature of chronic liver disorders, has been linked with oxidative DNA damage, insulin resistance and liver steatosis, and with triggering of hepatic stellate cells thus inducing liver fibrosis.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

While everyone knows that getting an adequate daily dose of vitamins and minerals is important in maintaining one's overall health, many question whether or not the vitamins touted in skin care products work in reducing the signs of sun-damaged skin.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

In an ongoing effort to scientifically validate the age-old belief that mind-body interventions have a beneficial impact on the health of patients, The University of Texas M. D. Anderson Cancer Center has been awarded more than $4.5 million to study the efficacy of incorporating yoga into the treatment program of women with breast cancer.

13 Apr 2010

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over AstraZeneca/Astellas's Seroquel (quetiapine), the sales-leading agent in the bipolar disorder drug market.

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

13 Apr 2010

Pancreaze Delayed Release Capsules receive FDA approval

The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.

13 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.

12 Apr 2010

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario.

12 Apr 2010

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute.

12 Apr 2010

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.

12 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

12 Apr 2010

Combating a frequently overlooked assassin: Water

When a hurricane, earthquake or wildfire strikes, a variety of supplies and equipment is needed to respond and aid victims. But, clean water is a common denominator; its demand is chronic and ubiquitous. In fact, dirty water is one of Mother Nature's overlooked assassins. More than one million people perish each year after imbibing it, and according to the World Health Organization, more than one billion people lack access to its clean counterpart.

12 Apr 2010

OptiMedica releases new details on femtosecond laser system for cataract surgery

OptiMedica Corp., a global ophthalmic device company, has released new details regarding the development of its proprietary femtosecond laser system for cataract surgery. The new system, which combines OptiMedica's breakthrough pattern scanning technology, an ultra-fast laser and integrated Optical Coherence Tomography imaging, is designed to dramatically improve the complex cataract procedure by replacing its most technically demanding and manual steps.

12 Apr 2010

Efficacy News and Research

Research finding suggests HCV interference with hepcidin synthesis

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Gilead Sciences doses first patient in Quad Phase III clinical program

Despite international guidelines, wide variations exist in breast cancer care

Pancreaze Delayed Release Capsules receive FDA approval

Researchers evaluate new treatment for coronary heart disease

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Competitive Technologies to introduce Calmare pain therapy at medical conference

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Global study shows wide variations in treatment of women with early breast cancer

Combating a frequently overlooked assassin: Water

OptiMedica releases new details on femtosecond laser system for cataract surgery

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News